Cold Atmospheric Plasma Is a Potent Tool to Improve Chemotherapy in Melanoma In Vitro and In Vivo.
Animals
Cell Line, Tumor
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Combined Modality Therapy
Dacarbazine
/ administration & dosage
Drug Therapy
Gene Expression Regulation, Neoplastic
/ drug effects
Gene Regulatory Networks
/ drug effects
Humans
Lipid Peroxidation
/ drug effects
Melanoma
/ drug therapy
Mice
Nitric Oxide
/ metabolism
Plasma Gases
/ administration & dosage
Xenograft Model Antitumor Assays
B16F10
apoptosis
combination therapy
dacarbazine
plasma medicine
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
08 07 2020
08 07 2020
Historique:
received:
26
03
2020
revised:
10
06
2020
accepted:
22
06
2020
entrez:
12
7
2020
pubmed:
12
7
2020
medline:
17
4
2021
Statut:
epublish
Résumé
Malignant melanoma is a devastating disease. Because of its aggressiveness, it also serves as a model tumor for investigating novel therapeutic avenues. In recent years, scientific evidence has shown that cold atmospheric plasma (CAP) might be a promising modality in cancer therapy. In this study, we aimed to evaluate the effect of CAP generated by an argon plasma jet alone or in combination with dacarbazine (DAC) on melanoma cells in vitro and in vivo. The effects of the CAP on inducing lipid peroxidation and nitric oxide production were higher in B16 melanoma cells in comparison to non-malignant L929 cells. Assays on cell growth, apoptosis, and expression of genes related to, e.g., autophagic processes, showed CAP to have a substantial impact in melanoma cells while there were only minoreffects in L929 cells. In vivo, both CAP monotherapy and combination with DAC significantly decreased tumor growth. These results suggest that CAP not only selectively induces cell death in melanoma but also holds promises in combination with chemotherapy that might lead to improved tumor control.
Identifiants
pubmed: 32650505
pii: biom10071011
doi: 10.3390/biom10071011
pmc: PMC7407977
pii:
doi:
Substances chimiques
Plasma Gases
0
Nitric Oxide
31C4KY9ESH
Dacarbazine
7GR28W0FJI
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Research and Technology Council of Mazandaran University of Medical Sciences
ID : 2878
Pays : International
Organisme : German Federal Ministry of Education and Research
ID : 03Z22DN11
Pays : International
Références
Antioxid Redox Signal. 2009 Apr;11(4):777-90
pubmed: 18828708
Proc Natl Acad Sci U S A. 2020 Feb 18;117(7):3687-3692
pubmed: 32029590
Cell Death Dis. 2014 Feb 13;5:e1056
pubmed: 24525732
Oxid Med Cell Longev. 2017;2017:4271065
pubmed: 28947928
Cancer Lett. 2011 Jan 28;300(2):105-14
pubmed: 21036469
Cancer Biol Ther. 2012 Nov;13(13):1299-306
pubmed: 22895073
Molecules. 2013 Apr 25;18(5):4917-28
pubmed: 23698040
Clin Cancer Res. 2009 Sep 1;15(17):5308-16
pubmed: 19706824
J Cell Biol. 1999 Feb 8;144(3):427-34
pubmed: 9971738
F1000Res. 2016 Jul 29;5:
pubmed: 27583134
Sci Rep. 2017 Jun 5;7(1):2791
pubmed: 28584285
Int J Mol Med. 2014 Oct;34(4):941-6
pubmed: 25050490
Cell Prolif. 2012 Dec;45(6):487-98
pubmed: 23030059
Curr Opin Oncol. 2008 Mar;20(2):183-9
pubmed: 18300768
Nat Rev Cancer. 2005 Sep;5(9):726-34
pubmed: 16148885
PLoS One. 2012;7(12):e52653
pubmed: 23300736
Biochim Biophys Acta. 2014 Dec;1843(12):2827-37
pubmed: 25173814
Stud Health Technol Inform. 2012;173:515-7
pubmed: 22357047
In Vivo. 2019 Jul-Aug;33(4):1011-1026
pubmed: 31280189
Sci Rep. 2018 May 16;8(1):7689
pubmed: 29769707
Annu Rev Cell Dev Biol. 2011;27:107-32
pubmed: 21801009
Biotechnol Bioeng. 2014 Mar;111(3):565-74
pubmed: 24022746
Sci Rep. 2018 Aug 24;8(1):12734
pubmed: 30143716
Mol Biol Cell. 2014 May;25(9):1523-31
pubmed: 24574456
In Vivo. 2014 Nov-Dec;28(6):1005-11
pubmed: 25398793
J Invest Dermatol. 2001 Aug;117(2):333-40
pubmed: 11511312
PLoS One. 2013 Sep 11;8(9):e73741
pubmed: 24040051
Cell Death Dis. 2018 Dec 5;9(12):1179
pubmed: 30518936
Phytomedicine. 2018 Mar 15;42:144-151
pubmed: 29655680
Pigment Cell Melanoma Res. 2008 Jun;21(3):358-67
pubmed: 18476909
Mol Aspects Med. 2018 Oct;63:88-98
pubmed: 29501614
Sci Rep. 2016 Feb 03;6:20332
pubmed: 26838306
PLoS One. 2010 Apr 02;5(4):e9996
pubmed: 20368806
Target Oncol. 2018 Aug;13(4):437-446
pubmed: 29667105
Oxid Med Cell Longev. 2019 Oct 8;2019:9062098
pubmed: 31687089
Autophagy. 2010 Apr;6(3):322-9
pubmed: 20224296
Pigment Cell Melanoma Res. 2014 Jul;27(4):525-39
pubmed: 24655414
Sci Rep. 2016 Jul 07;6:29048
pubmed: 27383714
Oxid Med Cell Longev. 2017;2017:4396467
pubmed: 28761621
J Vis Exp. 2017 Nov 17;(129):
pubmed: 29286412
Nature. 2011 Jan 20;469(7330):323-35
pubmed: 21248839
Free Radic Biol Med. 2019 Jan;130:71-81
pubmed: 30342190
Semin Cancer Biol. 2013 Oct;23(5):352-60
pubmed: 23831275
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Cell Commun Signal. 2017 Mar;11(1):97-104
pubmed: 28120184
PLoS One. 2014 Jun 27;9(6):e101299
pubmed: 24971517
Br J Cancer. 2011 Oct 25;105(9):1295-301
pubmed: 21979421
Adv Sci (Weinh). 2020 Mar 30;7(10):1903438
pubmed: 32440479
Sci Rep. 2019 Jan 24;9(1):634
pubmed: 30679720
Cell Death Dis. 2013 Oct 10;4:e838
pubmed: 24113172
Int J Oncol. 2005 Dec;27(6):1717-26
pubmed: 16273228
Biochem Pharmacol. 2018 Jul;153:51-61
pubmed: 29438677
Biosens Bioelectron. 2011 Oct 15;28(1):333-8
pubmed: 21820891
J Cell Biochem. 2012 Jul;113(7):2308-18
pubmed: 22345070
Cell Death Dis. 2013 May 23;4:e642
pubmed: 23703387
Cell Death Differ. 2018 Mar;25(3):486-541
pubmed: 29362479
Cell Signal. 2014 Mar;26(3):549-55
pubmed: 24308968
Chem Biol Interact. 2014 Jul 25;218:28-41
pubmed: 24802810
Int J Cancer. 2012 May 1;130(9):2185-94
pubmed: 21702038
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29
pubmed: 24399786
PLoS One. 2013 Aug 27;8(8):e73665
pubmed: 24013954
Oncotarget. 2017 Feb 28;8(9):15977-15995
pubmed: 27845910